Skip to main navigation
Orchestra BioMed logo

Close
Investor Relations
  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™
    • FreeHold Retractors
  • Investor Relations
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & Filings
    • SEC Filings
    • Annual Reports and Proxy Satements
  • IR Resources
    • Email Alerts
    • Contact IR
  • Contact Us
Menu - sns
Twitter Linkedin

Investor Relations

Releases Details

Daniel Burkhoff, MD, PhD, presented data from our MODERATO II double-blind, randomized study of BackBeat Cardiac Neuromodulation Therapy ™ at the 2020 Heart Rhythm Scientific Sessions online

May 8, 2020
PDF Version

Event: 2020 Heart Rhythm Scientific Sessions online

Webcast: HTTPS://CSLIDE-US.CTIMEETINGTECH.COM/HRS20/ATTENDEE/EPOSTER/POSTER/1407?Q=BURKHOFF

Orchestra BioMed logo

  • Footerlink - who we are

    Who We Are Our Approach Our People Careers

  • Footerlink - our innovations

    Our Innovations Pipeline Therapeutic Areas Virtue® SAB BackBeat CNT™ FreeHold Retractors

  • Footerlink - news & events

    Investor Relations Overview News & Events Stock Information Corporate Governance Financial & Filings IR Resources

  • Footerlink - contact us

    Contact Us
Menu - sns
Twitter Linkedin

© 2024 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Btn - disclaimer

Disclaimer